HHS Invests in New Antibiotics R&D Using Generative AI

Project aims to identify several novel antibiotic candidates to address the threat of antibiotic resistance

September 30, 2024

The U.S. Department of Health and Human Services (HHS) through the Advanced Research Projects Agency for Health (ARPA-H) will fund the Transforming Antibiotic R&D with Generative AI to stop Emerging Threats (TARGET) project, which will use AI to speed the discovery and development of new classes of antibiotics.

This program is another action to support the U.S.’s commitment to combating antimicrobial resistance (AMR), from innovation to international collaboration.

“Antibiotic resistance is a real and urgent threat affecting millions of people,” said Xavier Becerra, HHS secretary. “We need to prevent infections and conserve the antibiotics we have. We also urgently need new drugs to treat these increasingly resistant infections. This project will use AI to speed this needed innovation and help ensure we have the medicines we need to keep people alive.”

Bacterial infections are a leading cause of death worldwide, and new antibiotics development is needed as the prevalence of antibiotic-resistant bacteria grows. Conventional efforts to identify and develop new antibiotics require extensive manual screening and testing of molecular compounds, with the majority failing to show antibiotic activity. The laborious process impedes the ability to discover new antibiotics at the speed needed to address the urgent threat of antimicrobial resistance, HHS said. TARGET aims to close this gap by using deep learning to identify biomolecules with antibiotic and pharmaceutical potential and using generative AI to broaden the pool of candidate molecules.

“The rise of antibiotic resistance threatens to turn once-treatable infections into life-threatening ones, but with AI, we can accelerate the discovery of new antibiotics to address this threat like never before,” said Dr. Renee Wegrzyn, ARPA-H director. “With TARGET, ARPA-H is bringing together experts across antibiotic discovery, AI, and clinical testing to ensure we can refill the global pipeline of antibiotics and stop people from becoming seriously ill due to treatable infections.”

TARGET will be led by Phare Bio, along with the Collins Lab at the Massachusetts Institute of Technology (MIT) and Harvard’s Wyss Institute, with a budget of up to US$27 million. To accelerate the discovery and development of new antibiotics, the research team will focus on:

  1. Using generative AI to expand the number of antibiotic candidates. 
  2. Using generative AI to expand the number of antibiotic candidates. 
  3. Validating discoveries.

Latest Articles

Smart Equipment Trends in Commercial Cleaning for 2025
July 23, 2025 Joshua Woodworth

Smart Equipment Trends in Commercial Cleaning for 2025

July 21, 2025 Ronnie Phillips

The Dispenser Design Dilemma

July 18, 2025 Kevin Turpin

Connecting Facility Workers for Operational Excellence

Sponsored Articles

Riccardo Balducci, Group Sustainability Director at Sofide
July 17, 2025 Sponsored by Sofidel

The Sofidel Standard: A Bold Sustainability Journey With a Conscience

July 3, 2025 Sponsored by Tork, an Essity Brand

Setting a New Standard for Restroom Dispensers

July 3, 2025 Sponsored by SPARTAN CHEMICAL CO.

DfE-Certified Restroom Disinfectant—No PPE Required

Recent News

Nor’easter

Strongest Nor’easters Predicted to Intensify

Earn Cleaning Certifications at ISSA Show North America 2025

Minimum Wage Increased in 15 Cities, States in July